An Open-label, Non-randomized, 2-Period, Fixed Sequence, Single-center Study to Assess the Pharmacokinetics of Rosuvastatin and Simvastatin in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily

Trial Profile

An Open-label, Non-randomized, 2-Period, Fixed Sequence, Single-center Study to Assess the Pharmacokinetics of Rosuvastatin and Simvastatin in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2016

At a glance

  • Drugs Rosuvastatin (Primary) ; Simvastatin (Primary) ; Fostamatinib
  • Indications Hypercholesterolaemia; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Acronyms Statin DDI
  • Sponsors AstraZeneca
  • Most Recent Events

    • 09 Jan 2016 Results published in the Drugs in R and D
    • 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top